Xenon director exercises options for 3,500 shares

Xenon Pharmaceuticals Inc. director Steven Gannon exercised stock options to acquire 3,500 Common Shares at an exercise price of $7.38 per share.

Accepted by SEC EDGAR 05/13/2026 - 09:40 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. director Steven Gannon exercised stock options to acquire 3,500 Common Shares at an exercise price of $7.38 per share. This exercise-and-hold transaction increased his directly held stake to 10,641 Common Shares following the transaction. The underlying stock options were fully vested and exercisable and, after this exercise, no related options in this grant remain outstanding.

Insider Trade Summary

3,500 shares exercised/converted

Exercise 2 txns

Insider GANNON STEVEN

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,500	$0.00	$0.00
Exercise	Common Shares	3,500	$7.38	$26K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Shares — 10,641 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 3,500 to 0 contracts (Direct); Common Shares, 7,141 to 10,641 shares (Direct)

Footnotes (1)

1. F1. The shares subject to the option are fully vested and exercisable.

Key Figures

Options exercised: 3,500 shares Exercise price: $7.38/share Shares held after: 10,641 shares +2 more

5 metrics

Options exercised 3,500 shares Stock option exercise into Common Shares

Exercise price $7.38/share Conversion price for exercised stock options

Shares held after 10,641 shares Director’s direct Common Share holdings post-transaction

Derivative shares exercised 3,500 derivative shares Underlying Common Shares for the exercised options

Remaining options from this grant 0 options Total shares following derivative transaction for this option grant

Key Terms

Stock Option (Right to Buy), Common Shares, Exercise or conversion of derivative security, fully vested and exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" associated with 3,500 underlying Common Shares"

Common Shares financial

"security_title: "Common Shares" with 3,500 shares acquired and 10,641 held after"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security" for code M"

fully vested and exercisable financial

"Footnote: "The shares subject to the option are fully vested and exercisable.""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xenon Pharmaceuticals (XENE) director Steven Gannon report?

Steven Gannon reported exercising stock options to acquire 3,500 Xenon Pharmaceuticals Common Shares. The options had an exercise price of $7.38 per share and were fully vested and exercisable, indicating a routine conversion of derivative securities into directly held shares.

At what price did Steven Gannon exercise Xenon Pharmaceuticals (XENE) stock options?

He exercised stock options at an exercise price of $7.38 per Common Share. This price reflects the option’s pre-set conversion level, not necessarily the current market price, and resulted in 3,500 new Common Shares being issued to him directly.

How many Xenon Pharmaceuticals (XENE) shares does Steven Gannon hold after this Form 4 transaction?

Following the reported exercise, Steven Gannon directly holds 10,641 Common Shares of Xenon Pharmaceuticals. This post-transaction figure reflects the addition of 3,500 shares from the option exercise and shows his current visible equity position from this filing.

What happened to the stock options exercised by Xenon Pharmaceuticals (XENE) director Steven Gannon?

The 3,500 Stock Options (Right to Buy) were exercised and now show zero derivative securities remaining from that grant. They were fully vested and exercisable, and the exercise converted them into 3,500 directly held Xenon Pharmaceuticals Common Shares.

Was Steven Gannon’s Xenon Pharmaceuticals (XENE) transaction a buy or an exercise of options?

The Form 4 shows an exercise of stock options, not an open-market purchase. Code “M” indicates a derivative exercise, where 3,500 options at $7.38 per share were converted into 3,500 Common Shares held directly after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GANNON STEVEN

(Last) (First) (Middle)

3650 GILMORE WAY

(Street)

BURNABY BRITISH COLUMBIA, CANADA V5G 4W8

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/12/2026		M		3,500	A	$7.38	10,641	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.38	05/12/2026		M			3,500	(1)	06/01/2026	Common Shares	3,500	$0	0	D

Explanation of Responses:

1. The shares subject to the option are fully vested and exercisable.

	/s/ Nathaniel Adams, Attorney-in-fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)